Valneva Austria Gmbh and Intercell | Date: 2004-09-28
[ chemicals for use in the pharmaceutical industry to manufacture diagnostic and therapeutic biological products for diagnosis, treatment, and monitoring of cancers, infectious diseases and other chronic diseases ]. vaccines [ and bio-pharmaceutical preparations ] for use in human [ and veterinary ] medicine, namely, for the treatment of [ cancers, ] infectious diseases and other chronic diseases, namely, Encephalitis, [ Hepatitis C, Tuberculosis, bladder cancer, travellers diarrhea and Streptococci; diagnostic and therapeutic biological pharmaceutical preparations for diagnosis, treatment and monitoring of cancer, infectious diseases and other chronic diseases, namely, Encephalitis, Hepatitis C, Tuberculosis, bladder cancer, travellers diarrhea and Streptococci ]. [ scientific apparatus used for diagnosis, treatment and monitoring of cancer, infectious diseases and other chronic diseases, namely, test tubes, microscopes, and retorts ]. [ surgical and medical instruments and apparatus for use in medical analysis and blood testing namely, bougies, cannulae, injectors, probes, scalpels ]. [ product research and development, namely, development of medical test methods; chemical, medical, pharmaceutical and bacterialogical research ].
Agency: Cordis | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.06M | Year: 2012
Vaccines are the most cost-effective health interventions available (WHO). The impact of vaccination on the health of the worlds population cannot be overstressed. Vaccinolgy is the multidisciplinary discipline of developing vaccine interventions it combines knowledge from basic sciences, medical sciences, public health and social sciences. Ideally a vaccinologists would be able to have a general overview of all disciplines involved but at the same time be able to zoom in on its own discipline. There is hardly any formal training to become a vaccinologist in the world and none such training exists at a PhD level in Europe. The need for a program to train vaccinologists is apparent and recognised . The vaccine industry is a largely European based industry. Investing in the future of this industry by training the next generation vaccinologists will boost Europeans economy will provide high quality employment and will sustain Europeans competitiveness. Clearly there are public health and economic reasons to invest in a training program training the European vaccinologists of the future.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2011.1.4-4 | Award Amount: 40.88M | Year: 2011
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise. A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. ADITEC scientists and institutions are part of the Sclavo Vaccines Association (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.